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 16 
Summary 17 
Difficulties with walking and balance are common among people with Parkinson disease 18 
(PD).   Effective management of these walking and balance problems is critical, as these issues 19 
can contribute to decreased mobility, falls, social isolation, reduced quality of life, and increased 20 
mortality.  This review provides an overview of the gait and balance disorders associated with 21 
PD and discusses the methods currently utilized to manage gait and balance problems among 22 
people with PD.  These methods include pharmacological, surgical, and rehabilitative 23 
approaches.  Remaining challenges and future directions, including the need for 24 
comprehensive, multidisciplinary, patient-centered care provided by qualified movement 25 
disorders experts, are also highlighted. 26 
 27 
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     What is Parkinson Disease? 30 
Parkinson disease (PD) is a progressive neurodegenerative disorder that affects 31 
between 1-2% of individuals over 65 years of age and 3-5% of those 85 or older [1].  Age 32 
appears to be the greatest risk factor for PD, but many other contributing factors have also been 33 
identified [2-4].  At present, PD affects 1-1.5 million people in the United States and an 34 
estimated 40 million people worldwide.  The number of individuals with PD will increase in 35 
coming decades, as the percentage of the U.S. population over age 65 rises from its current 36 
level of 12% to over 20% by 2030 [5].   37 
PD is characterized by four cardinal features: tremor, bradykinesia, rigidity, and postural 38 
instability.  The symptoms of PD arise only after substantial loss of dopaminergic neurons in the 39 
substantia nigra pars compacta.  In fact, PD was originally attributed only to neuronal loss within 40 
the substantia nigra pars compacta, and a concomitant loss of dopamine.  Pharmacologic 41 
replacement of dopamine is the most common, and arguably most effective, treatment for PD.  42 
However, PD is now thought to involve not only the dopaminergic system, but also other 43 
neurotransmitter systems whose role may become more prominent as the disease progresses 44 
[6].  These non-dopaminergic systems may be particularly implicated in balance and gait 45 
disorders, the management of which is the focus of this paper.  Balance and gait impairments 46 
are particularly problematic for individuals with PD, as they can lead to falls, injury, and fear of 47 
future falls.  As a result of injury and/or fear of falling, individuals may limit their physical activity 48 
which may result in social isolation as well as subsequent muscle weakness and osteoporosis.  49 
These in turn may contribute to increased risk of future falls and fall-related injuries [7].  The 50 
purpose of this paper is to provide an overview of the gait and balance disorders associated 51 
with PD and discusses the methods currently utilized to manage gait and balance problems 52 
among people with PD. The ideal combination and prioritization of these approaches needs to 53 
be determined on an case by case basis.   54 
 55 
Gait, Balance, and Falls in Parkinson Disease 56 
Gait Impairments 57 
Many individuals with PD have gait difficulties that greatly limit functional mobility.  The 58 
majority of studies focusing on Parkinsonian gait examined walking in a straight line.  These 59 
studies showed that straight ahead walking in PD is characterized by: 1) a flexed posture, 2) 60 
short, shuffling steps, 3) deficits in stride length regulation, 4) reduced foot clearance during 61 
swing, 5) increased cadence, 6) limited extension at the hip and knee and reduced ankle 62 
plantarflexion, 7) reduced transverse rotation of the trunk and pelvis, 8) inappropriate 63 
coactivation of muscle agonist-antagonist pairs, and 9) reduced muscle activation amplitudes [8-64 
14]. The cause of these gait impairments is thought to be a disturbance in the motor set function 65 
of the basal ganglia, which is involved in regulation of movement amplitude [15]. It has also 66 
been hypothesized that the basal ganglia contribute to the regulation of postural alignment and 67 
motor control, which may play a role in gait dysfunction in PD [16,17]. 68 
People with PD often have even more difficulty walking in challenging situations than they 69 
do walking forward.  For example, individuals with PD experience exacerbated gait impairments 70 
when required to perform a concurrent task.  Specifically, during dual task walking, gait speed 71 
and step length are reduced and stride to stride variability is increased relative to single task 72 
walking [18-23].  In backward walking, gait speed and stride length are also reduced relative to 73 
forward walking in people with PD compared to people without PD [24,25].  Both dual task 74 
walking and backward walking have been recommended as important tasks to evaluate when 75 
assessing gait in people with PD.   76 
In addition to difficulties with dual task walking and backward walking, many people with PD 77 
have more difficulty turning while walking than they do walking in a straight line.  Individuals with 78 
PD, particularly those with a history of freezing or falls, use an increased number of steps to turn 79 
as compared to people without PD [26,27].  People with PD also tend to turn en bloc, i.e. 80 
rotating the head and trunk simultaneously rather than in sequence, and require greater time to 81 
turn [28-30].  The work of Crenna et al. [28] is particularly interesting because it reveals that 82 
turning deficits are present even in individuals with mild PD who as yet have no alteration or 83 
impairment in their straight walking.  This suggests that turning difficulty may affect individuals 84 
with PD even from a very early stage of the disease when other motor symptoms are not yet 85 
apparent.  86 
Turning is particularly problematic because it is one of the primary triggers for freezing of 87 
gait (FOG).  FOG, “an episodic inability (lasting seconds) to generate effective stepping”, affects 88 
more than 50% of patients who have had PD for over 5 years [31,32].  FOG commonly occurs 89 
during turning, but may also occur at gait initiation or when walking through doorways or other 90 
narrow spaces.  Those who experience FOG are more negatively affected than those without 91 
FOG by challenging conditions like dual task walking and backward walking [25].  FOG is a 92 
prominent cause of falls, particularly during turning [33-35].  Falls that occur during turning are 93 
eight times more likely to result in hip fracture than falls during straight line walking [36].   94 
 95 
Balance Impairments 96 
Postural instability is one of the cardinal symptoms of PD. Though it is often associated 97 
with mid-to-late disease progression, recent studies have shown subclinical manifestations of 98 
postural instability in the early stages of PD as well [37-40]. Many different factors are believed 99 
to contribute to postural instability including impaired peripheral sensation and somatosensory 100 
integration, decreased strength, axial rigidity, and impaired postural responses [41-46]. 101 
Disturbed motor programming within the basal ganglia as well as abnormally processed 102 
proprioceptive signals are thought to be underlying causes of postural instability in PD [47]. 103 
Recent studies have also consistently shown that postural instability is not relieved with 104 
dopaminergic medication, therefore, non-dopaminergic pathways have been hypothesized to 105 
contribute to postural instability [48, 41].  106 
Many different modes have been used to quantify instability in PD. In a clinical setting, 107 
quick screening of postural instability may include the UPDRS Retropulsion/Pull test [49] or the 108 
Push and Release test [50]. Assessments of static postural control have found that individuals 109 
with PD have increased sway area and abnormal shifts in the center of pressure [38, 39, 51]. 110 
Dynamic posture, such as during gait and functional activities, has also been shown to be 111 
impaired with slower velocities of movement and decreased ability to move the center of mass 112 
appropriately [40, 42, 46, 52, 53]. 113 
Both anticipatory postural adjustments and reactive postural adjustments are impaired in 114 
individuals with PD, with decreased amplitude and coordination of these movements [40, 54, 115 
55].  An association exists between fear of falling and postural instability, though whether it is a 116 
causative relationship or a correlation is unclear [56]. However, postural instability is also related 117 
to falls in individuals with PD [57-59].  118 
 119 
Falls 120 
 Individuals with PD are five to nine times more likely to sustain recurrent falls than age-121 
matched individuals without PD [60, 61]. Falls and fractures are the primary reason for hospital 122 
admissions in individuals with PD [62, 63]. Studies have shown that 25-32% of falls result in 123 
injury [58, 64] with at least 3% [65] resulting in serious injury requiring medical attention. These 124 
are substantial numbers considering in prospective studies, 45-68% of individuals with PD will 125 
fall during a 12 month period with 29-51% experiencing two or more falls [58, 61, 64, 66]. In a 126 
given six-month period 29% of individuals with PD without a history of falling will experience 127 
their first fall [43]. Furthermore, individuals with PD have a 3.2 fold greater risk of hip fracture 128 
than age-matched individuals without PD [67]. Falls and subsequent hip fractures carry 129 
substantial personal costs, such as fear of falling, withdrawal from social activities, and a 130 
decreased quality of life [7, 68]. Hip fractures also represent a substantial financial burden to 131 
society, with the cost of hip fracture care in individuals with PD totaling approximately $192 132 
million per year in the United States alone [69, 67]. One study suggests that frequent falls in an 133 
individual with PD can be used as a marker to predict life expectancy [70]. 134 
 The majority of falls in this population occur in the home and have intrinsic causes (i.e. 135 
disease processes such as postural instability, freezing, loss of concentration, etc.) as opposed 136 
to extrinsic causes (i.e. a wet floor, obstacle, etc.) [60, 64, 65]. Falls often occur during transfers, 137 
when bending or reaching, while walking especially in dual task situations, and during turning as 138 
well as due to freezing and tripping/accidental causes [7, 60, 64, 65]. It is interesting to note that 139 
2/3 of individuals who fell said their signs and symptoms were under control when they fell [60].  140 
 Many studies have compared individuals with PD who fall and those who do not fall. 141 
Those who fall tend to have longer disease duration, increased disease severity, a history of 142 
previous falls, increased levodopa replacement medication use, and increased freezing and 143 
dyskinesia [64, 71, 43, 58, 59]. They perform more poorly in balance and functional mobility 144 
measures, have increased fear of falling, have increased sway in standing, and have decreased 145 
lower extremity strength [60, 71, 43, 72, 59]. Cognitive factors such as decreased memory, 146 
power of attention, and reaction time have also been shown to be associated with falling [64, 147 
58]. Though cardiovascular issues such as orthostatic hypotension and postprandial 148 
hypotension have been shown to be present in individuals with PD, their contribution to falls has 149 
been debated [64, 43, 58, 73].  150 
 151 
Therapeutic Approaches to Management of Gait and Balance in Parkinson Disease 152 
Pharmacological Treatment 153 
 Levodopa (L-DOPA) is often the drug of choice in the pharmacologic management of 154 
motor symptoms in PD as it replaces endogenous dopamine which is reduced in individuals with 155 
PD [74]. Bradykinesia and rigidity often respond well to treatment with L-DOPA, while there is 156 
increased variability in response with respect to tremor [75]. The introduction of L-DOPA also 157 
has proven to be beneficial in improving gait disturbances. Several gait parameters are 158 
negatively influenced by withdrawal of L-DOPA therapy [26]. The parameters most consistently 159 
impacted when patients are off  L-DOPA are stride length and speed [76-84]. Additional features 160 
noted in individuals off L-DOPA include decreased arm swing and reduced trunk rotation, 161 
decreased ground reaction forces and reduced range of motion at the knee [85], and reduced 162 
plantarflexor power [84]. Many studies have demonstrated that stride length and gait speed are 163 
responsive to L-DOPA, with one study showing an increase of 0.25 meters/sec from off to on 164 
medication [86, 80], while other parameters such as stance duration and arm swing are dopa-165 
resistant [8, 76-78, 87]. These dopa-resistant aspects of gait support the idea that the pathology 166 
of PD extends further than just the nigrostriatal dopaminergic system [75].  167 
 Freezing of gait (FOG) is one of the most debilitating and least understood gait 168 
disturbances in PD [88]. Treatment of freezing is often extremely difficult, and specifically 169 
regarding L-DOPA, results are mixed. Those patients who experience FOG during the off state 170 
often experience improvements in freezing after taking L-DOPA [89]. Schaafsma and 171 
colleagues found that among those participants who experience primarily off state freezing, 172 
FOG episodes occurred more frequently, had a longer duration, and also involved significant 173 
akinesia. In the same study, the observation of FOG in the on state was quite different as the 174 
episodes occurred less frequently, had a shorter duration, and did not involve complete blocks 175 
in movement [90]. Individuals with PD experiencing on state freezing present a much more 176 
challenging problem as their FOG is not responsive to L-DOPA. This problem is considered to 177 
be quite rare [88], and it has been suggested that dopaminergic agents be reduced in 178 
individuals with on period freezing [91]. For patients experiencing FOG that is resistant to L-179 
DOPA, other therapeutic options may be considered [92]. 180 
 Some alternative pharmacologic approaches aimed at treating FOG have been 181 
somewhat effective, while others have not. Selegiline, an MAO-B inhibitor, was shown to be 182 
effective in reducing the development of FOG in patients with early PD [93]. Shoulson and 183 
colleagues found similar results in individuals in the advanced stages of PD [94, 95], and it is 184 
suggested that this may be of greater clinical significance as FOG and falls are highly related in 185 
the later stages of PD [92]. Rasagiline, another MAO-B inhibitor, has also been shown to have a 186 
positive effect on FOG, however, the clinical significance of this improvement is not yet 187 
understood [92]. Amantadine has been shown to have conflicting results with respect to FOG. 188 
Giladi and colleagues reported that those treated with amantadine were less likely to develop 189 
FOG [96], while Macht and colleagues reported an association between treatment with L-DOPA 190 
and amantadine and increased FOG frequency [97]. Botulinum toxin was originally found to 191 
have a positive effect on FOG [98, 99]; however, Gurevich and colleagues found dissimilar 192 
results and also found that botulinum toxin increased fall risk [100]. Methylphenidate has also 193 
been examined as a treatment for FOG [101, 102]. In a study examining apomorphine, an 194 
alternative option for those with advanced PD with motor complications, researchers found that 195 
FOG was not improved following a single dose of this medication [103]. In summary, FOG 196 
remains a substantial problem that is not well addressed by current pharmacologic approaches. 197 
 198 
Deep Brain Stimulation 199 
 Surgical intervention, in the form of deep brain stimulation (DBS), is an increasingly 200 
common treatment method often employed in advanced stages of PD where pharmacological 201 
therapy does not adequately control parkinsonian symptoms and/or complications such as 202 
wearing off of medication and levodopa-induced dyskinesias have developed. With the intent of 203 
improving the predominant symptoms in PD, including gait disturbances and postural instability, 204 
the favored target for stimulation is most often the subthalamic nucleus (STN) [104]; however, 205 
there is conflicting evidence regarding gait improvement following STN stimulation in those with 206 
PD [105-110]. It is important to note that stimulation of the internal globus pallidus (GPi) has 207 
been a target for DBS in the past, but STN stimulation is now preferred by many because the 208 
antiparkinson medications can typically be reduced more following STN as compared to GPi 209 
surgery, and less stimulation energy is needed [111]. Recently, support for stimulation of the 210 
pedunculopontine nucleus (PPN) [112-114] has gained traction among surgeons, but again, 211 
evidence supporting this technique without pairing it with STN stimulation is controversial [115]. 212 
It is imperative that healthcare professionals understand these surgical techniques and how 213 
they may affect gait and balance in individuals with PD so that intervention plans may be 214 
designed properly. 215 
 Using quantitative measures, STN stimulation has been shown to improve gait 216 
parameters such as stride length and gait velocity [109]. In a meta-analysis conducted by 217 
Bakker et al., bilateral STN stimulation was found to improve gait disturbances and postural 218 
instability, as assessed by the UPDRS, in the off medication state [108]. When examining anti-219 
Parkinson medication and STN DBS and their effects on gait and gait stability, Hausdorff et al. 220 
[110] noted that combined effects of medication and DBS on gait speed, stride length, and gait 221 
stability were larger than effects of DBS alone.  Krack et al. [107] reported that STN stimulation 222 
provided an initial improvement in gait and postural instability, but performance declined with 223 
time, and by five years, patients’ gait disturbances and postural instability were more impaired 224 
than prior to surgery. For those patients experiencing freezing of gait (FOG) that is responsive 225 
to levodopa (L-DOPA), STN stimulation has been shown to fully replicate the L-DOPA induced 226 
improvement seen prior to surgery [107, 116-119]. However, regarding L-DOPA resistant FOG, 227 
STN stimulation has proven to be ineffective [120, 121, 116, 118]. As such, new surgical targets 228 
are necessary to determine if DBS surgery is effective at improving FOG in individuals with PD.    229 
 It has been proposed by previous reports that the PPN plays a role in the origination of 230 
PD motor symptoms, particularly gait disturbances and postural instability [122, 123]. Moro and 231 
colleagues examined UPDRS II, III, and IV scores as well as sub-scores in six subjects at three 232 
and 12 months post unilateral PPN stimulation [114]. At three months post-surgery, UPDRS II 233 
scores significantly improved, predominantly due to marked decreases in sub-scores for falling 234 
and freezing [114]. The UPDRS III scores (including gait, postural stability) demonstrated a 235 
trend toward improvement; however the scores did not reach significance [114]. UPDRS II sub-236 
scores for falling at 12 months were similar to those at three months, and UPDRS III scores 237 
trended toward significant improvement from three to 12 months post-implantation [114]. In 238 
contrast, Stefani et al. found that in the off medication state, PPN DBS alone did not improve 239 
UPDRS III scores [115]. It was also found that PPN DBS + STN DBS when on medication 240 
improved UPDRS II scores [115]. In both on and off medication states, dramatic improvements 241 
in gait and balance were found in two patients post-PPN stimulation. It is important to note that 242 
these differences were found 42 (patient 1) and 16 (patient 2) days post-surgery and as such 243 
micro-lesion effects from the surgery might still have been present. Repeated clinical 244 
observations at time points more than 3 months post-surgery are necessary to avoid micro-245 
lesion and placebo-like effects following this type of procedure [124]. In summary, while the 246 
PPN, especially when paired with STN DBS, has recently been proposed as a surgical target for 247 
improving gait and balance in those with PD, it is not yet recommended as a substitute for STN 248 
DBS [115]. Current evidence is limited by questions regarding electrode targeting and in some 249 
studies it is not clear that electrodes were successfully placed within the PPN.  More data are 250 
needed to confirm or refute PPN DBS efficacy on gait and balance deficits in those with PD. 251 
 252 
Physical Rehabilitation 253 
Treadmill Training  254 
 Recently, the effects of treadmill training (TT) on gait parameters, balance, quality of life 255 
(QOL), and functional tasks have been examined to determine efficacy of this intervention for 256 
people with PD. Mehrholz et al. conducted a systematic review of studies investigating the 257 
effects of TT on specific gait parameters in those with PD [125]. Eight small studies were 258 
included and improvements were noted in gait speed, stride length, and walking distance when 259 
comparing individuals who underwent TT and controls [125]. With regards to training intensity, 260 
Fisher et al. reported that high-intensity TT yielded significant improvements in self-selected gait 261 
speed, stride length, step length, and gait kinematics [126]. When compared with conventional 262 
gait training, structured TT led to significant improvements in over-ground walking speed (1.37 263 
m/s pre to 1.56 m/s post-training) and stride length (0.72 m pre to 0.78 m post-training), as well 264 
as double stance duration [127]. Miyai et al. studied body weight-supported treadmill training 265 
(BWSTT) versus conventional physical therapy in individuals with PD and found the BWSTT 266 
group maintained improvements in gait speed and stride length at one and four months post 267 
intervention [128]. Multi-directional TT (forward, backward, sideways) and step-perturbation 268 
training have also been shown to improve cadence and gait speed in men with PD [129].  269 
While gait parameters are commonly measured when investigating the effects of TT, 270 
other studies have examined its effects on a variety of other outcome measures. Studies by 271 
Cakit et al. and Protas et al. have shown that different protocols for TT can improve balance 272 
[130], decrease fear of falling [130], and decrease number of falls [129].  A six week TT program 273 
in which participants with PD walked at 70%-80% of maximal heart rate led to improvements in 274 
lower extremity functional tasks (20-m walking time, timed U-turn, turning around a chair, 275 
ascending/descending stairs, standing from a chair, and standing on one foot) [131]. In addition 276 
to improvements in lower extremity capabilities and balance, Hermann et al. found that TT 277 
significantly improved QOL [132]. 278 
The mechanisms by which TT improves gait in individuals with PD are not yet fully 279 
understood. In a recent study by Bello and colleagues examining these mechanisms, the 280 
authors theorized that gait improvements following TT are related simply to the belt movement 281 
on the treadmill, which forces stepping through stretch facilitation of hip flexors and 282 
plantarflexors and the termination of the stance phase [133]. Other studies support the idea that 283 
TT forces step lengthening and may be an influential factor in gait improvements [9, 134, 135]. 284 
Protas et al. [129] hypothesized that visual and auditory cues, which have been shown to 285 
positively impact gait and balance in those with PD [136], provided by the treadmill could have 286 
lead to improvements in gait and balance, respectively. Herman et al. theorized that perhaps the 287 
treadmill provides an external rhythm that compensates for the ineffective internal rhythm of the 288 
basal ganglia in those with PD. Another idea proposed by Herman et al. acknowledges that the 289 
intense, repetitive TT may add to motor learning which may explain the lasting improvements in 290 
gait five to six weeks post TT [132]. 291 
 Although limited, there is good evidence supporting the short-term benefits of TT for 292 
people with PD. While the mechanisms behind the gait and balance improvements are not yet 293 
fully understood, the literature documenting such improvements should not go unnoticed. As 294 
such, rehabilitation professionals should consider TT as an adjunct to over-ground gait training 295 
for people with PD.  296 
 297 
Use of External Cues and Assistive Devices 298 
External cues are thought to benefit individuals with PD by bypassing the degenerated 299 
basal ganglia and utilizing other neural pathways. It is hypothesized that external cues act via 300 
the parieto-premotor pathways or the cerebellar circuits [22, 137]. Auditory, somatosensory, and 301 
visual cues have all been studied. 302 
 Auditory cueing has been shown to improve speed, cadence, stride length, and gait 303 
variability, though some studies have shown it has less effect on stride length and gait initiation 304 
than visual cueing [22, 138-141]. Auditory and somatosensory cues are comparable for 305 
improving turning velocity and in dual task situations in individuals with PD [142, 143]. Visual 306 
cueing can increase push off and improve gait initiation, and it has been shown to be most 307 
effective at increasing stride length [22, 138]. Some studies have demonstrated, though, that 308 
visual cues may decrease cadence and can interfere with dual task items [22, 140].  309 
Some studies have attempted to combine different cueing types to see if they have an 310 
additive effect. When visual and auditory are combined for gait, it is less effective than either 311 
separately [140].However, when an audiovisual system was used to cue sit-to-stand transfers, 312 
speed and torque of the transfer were better than without cueing [144].  An attentional strategy 313 
and auditory cueing combined are effective in improving gait [143, 145, 146]. 314 
In a recent review of cueing for individuals with FOG, Nieuwbower [147] concluded that 315 
visual cueing may benefit movement initiation while auditory may be more effective to maintain 316 
gait symmetry and timing, though neither was able to consistently prevent FOG.  Cueing should 317 
be individually altered, as some cueing can induce freezing in some individuals, and on-FOG 318 
and off-FOG may respond differently [147]. Freezers tend to benefit more from cueing during 319 
turns and at -10% of their preferred pace for normal walking [141, 142].  320 
Bryant et al. [148] sent individuals home with an auditory stimulator that had been 321 
programmed during an initial evaluation. After one week of individuals practicing at home for 30 322 
minutes a day, gait speed and stride length showed improvement, and 90% of participants 323 
thought the device was helpful and easy to use [148]. Self-cueing techniques can be utilized as 324 
well. Counting out loud, saying standard phrases, and singing are sometimes used [149]. 325 
Teaching individuals to sing in their heads while performing activities has been shown to 326 
improve gait and turning in individuals with mild to moderate PD [150].  327 
Dual task walking seems to benefit more from cueing than single task walking in 328 
individuals with mild to moderate PD. In theory, the cueing allows an individual to decrease the 329 
amount of attention necessary for gait, freeing up more attention for the secondary task [139, 330 
143]. 331 
Recent studies have shown short-term carry over after training, though it is believed that 332 
the cue must continue to be present to be effective long-term. Training with auditory cues for 333 
eight weeks, three times a week while increasing the tempo allowed a plateau in progress to be 334 
met, with a benefit in gait parameters (stride length, velocity, and cadence) being sustained six 335 
weeks later [151]. Other studies of shorter cue-training duration have shown shorter carryover in 336 
turning, dual task benefits, and fear of falling [142, 143]. 337 
Long-term delivery of cues may be accomplished via specialized assistive devices [152]. 338 
Assistive devices such as canes and walkers are frequently prescribed for people with PD and 339 
can be modified to include a laser that projects lines on the floor that serve as visual cues to 340 
facilitate gait.  Other devices may offer additional postural support beyond that offered by 341 
traditional devices [153].  Limited studies have been conducted to date to determine which 342 
assistive devices are optimal, but some guidance is available in the literature [154, 155].  343 
Emerging devices may also hold promise for the treatment of FOG [156]. 344 
 345 
Resistance Training 346 
 Evidence suggests that muscle force production is reduced in individuals with PD, even 347 
in early stages of the disease, when compared to age-matched controls [157].  In fact, muscle 348 
weakness has been described as a primary symptom of PD [158].  Resistance training has 349 
been shown to be an effective intervention for improving strength, muscle mass, and function in 350 
healthy older adults [159]; however, evidence supporting the efficacy of this type of intervention 351 
for individuals with PD is currently limited. Falvo and colleagues suggest that resistive exercise 352 
may reduce the presence of PD sequelae such as impaired motor function, muscle and bone 353 
weakness, as well as reduced quality of life (QoL) and fear of falling, and as such stress the 354 
need for well-controlled clinical trials examining high-intensity resistance training in those with 355 
PD [160]. 356 
 Recently, Dibble et al. studied the effects of a 12 week high-intensity, eccentric 357 
resistance training program on a variety of outcome measures for individuals with PD [161]. The 358 
investigation compared an active control group and an experimental group, both of which 359 
partook in the same resistance traditional resistance training program; in addition, the 360 
experimental group completed high-intensity eccentric training, while the control group did not.  361 
The experimental group had significant improvements in lower extremity muscle force, 362 
bradykinesia (measured by functional walking tasks), and QoL [161]. Similar results were found 363 
in a study examining eccentric resistance training and its effects on muscle structure, stair 364 
descent, and six minute walk test (6MWT) in individuals with PD [162].  Regarding specific gait 365 
parameters, Scandalis et al. found that an eight week strengthening program improved stride 366 
length (0.83 m pre to 0.95 m post-training) and walking velocity (1.0 m/sec change pre to post-367 
training) in individuals with PD [163]. Examining the effects of resistance training on balance, 368 
investigators have found that those with PD undergoing both balance and resistance training 369 
demonstrated significant improvements in balance and muscle strength [164, 165].  370 
 371 
Balance Training 372 
Balance training is a priority for individuals with PD to address postural instability. A 373 
recent systematic review by Dibble et al.[166] found moderate evidence supporting exercise-374 
induced improvements in balance performance in mild to moderate PD. Keus et al.[167] 375 
recommend balance training as one of the top four recommendations for physical therapy, and 376 
the majority of exercise programs include some form of balance training [149, 166, 168-171]. 377 
Many mixed exercise programs (not balance training exclusively) have shown improvement in 378 
balance assessments (i.e. TUG, BBS, 5-step test speed) and during functional activities (i.e. 379 
gait parameters, turning, possible decrease in falls) after treatment [166, 169, 172]. Each of 380 
these treatment protocols has been studied for different durations and frequencies, most without 381 
specifying the length of balance training specifically. Many different modes of balance training 382 
can be utilized including, but not limited to, perturbations on a treadmill, calisthenic/balance 383 
exercises, practicing functional tasks that require increased balance, and balance specific 384 
training on a force plate [166, 171-173]. Further details on activities included in the balance 385 
exercise portion of treatments are not specifically described in most studies and, therefore, 386 
cannot be compared between studies.    387 
 An individual’s confidence in his balance should also be addressed during balance 388 
training, as decreased balance confidence and fear of falling can negatively impact quality of life 389 
and are associated with falls [167]. Whole body vibration was thought to increase balance in 390 
individuals with PD, however, more recent studies show no added benefit using this form of 391 
therapy [174, 175]. Some individuals with PD might also have vestibular deficits that contribute 392 
to their balance impairment; some studies show vestibular rehabilitation techniques may be 393 
beneficial [176, 177].   394 
 395 
Flexibility Exercises 396 
Since rigidity is known to be one of the cardinal symptoms of PD, stretching is often 397 
recommended to be included in a rehabilitation program for this population [167, 170, 149]. 398 
Many exercise protocols that have shown improvement in individuals with PD include stretching 399 
or flexibility as one component of the program [57, 169, 172, 171]. Increased rigidity in the hip 400 
and trunk musculature in individuals with PD has been focused on as it is thought that this 401 
increased axial rigidity may contribute to poor posture and abnormal coordination during walking 402 
and turning [42, 178, 179]. Individuals with PD may have decreased axial flexibility, which can 403 
contribute to decreased functional reach [180, 181]. 404 
 Very few studies have truly examined the outcomes of a stretching or flexibility program 405 
in individuals with PD. Since studies have shown that axial rigidity is not affected by levodopa 406 
replacement therapy, a stretching program may be an effective alternative [182, 179]. Flexibility 407 
training has been shown to improve functional reach with subjective improvements in daily tasks 408 
such as driving, scratching their back, and rolling in bed but not in other functional tasks such as 409 
stand to supine time or six-minute walk distance [180]. The flexibility training focused on 410 
decreasing overall activation, relaxation into stretches with emphasis on axial structures, and 411 
performing functional task [180]. A promising study by Bartolo et al.[183] evaluated a 412 
rehabilitation protocol for individuals with PD who also had lateral trunk deviations. During this 413 
exercise program, which included stretching and relaxation exercises, functional strengthening, 414 
and gait and balance training, emphasis was placed on correcting postural trunk deviations and 415 
improving trunk control. They found improved posture, flexibility, and trunk mobility with gains 416 
lasting up to six months [183].  417 
In a recent article presenting a new exercise program framework, King and Horak [170] 418 
summarize that rigidity impacts posture by increasing flexor tone, decreasing trunk range of 419 
motion during functional tasks and walking, and increasing muscular co-contraction which is 420 
unfavorable during automatic postural responses. They suggest that activities be performed that 421 
have increased emphasis on trunk and head rotation, postural awareness/erect alignment, 422 
flexor muscle lengthening, and increasing limits of stability [170]. As of now, this exercise 423 
program has not been evaluated for its effectiveness.  424 
Neck rigidity, which is also greatly increased in individuals with PD, has recently been 425 
shown to correlate with posture and gait as well as have significant impact on functional mobility 426 
and balance [182]. At this time, no studies have addressed the efficacy or effectiveness of 427 
stretching or neck flexibility exercises on neck rigidity or functional tasks. In summary, there is 428 
very little research that supports stretching in individuals with PD; however, expert opinion 429 
continues to prioritize the inclusion of stretching and flexibility exercises in rehabilitation and 430 
prevention exercise regimens for individuals with PD [169, 172, 167, 170, 149, 171]. 431 
                                     432 
Alternative Exercise Programs 433 
Alternative modes of exercise such as dance and Tai Chi have also been shown to be 434 
effective for improving balance and gait function in individuals with PD.  Dance may be ideally 435 
suited to those with PD, as it is a social activity that is inherently motivating [184].  Dance is also 436 
performed to music which can provide an external cue to facilitate movement.  In addition, 437 
dance involves the teaching and practice of specific movement strategies and incorporates 438 
dynamic balance challenges.  Dance can also result in improved cardiovascular function, a 439 
testament to the fact that, if done with sufficient intensity, dance is an excellent form of aerobic 440 
exercise [185, 186].  Several studies have reported significant improvements in balance, six 441 
minute walk distance, and gait velocity in groups with PD who participated in Argentine tango or 442 
waltz/foxtrot classes [187-191].  For a comprehensive review of the literature regarding dance 443 
and PD please see Earhart [192].  For recommendations on implementing dance classes for 444 
individuals with PD see Hackney & Earhart [193]. 445 
Tai Chi is another alternative exercise approach that has been examined in several 446 
studies with mixed results (for review see 194).  Two studies have specifically reported balance 447 
outcomes, and both noted reduced falls or improved balance [195, 196].  Many of the Tai Chi 448 
studies are limited by a small sample size and some also lack a control group.  It is also unclear 449 
whether Tai Chi is superior to traditional exercise, as one study found no differences between a 450 
conventional exercise group and a Tai Chi group [197].   451 
 452 
Multidisciplinary Care Approaches 453 
Most care for individuals with PD is currently performed on an outpatient basis using 454 
monodisciplinary care [198]. Few studies have assessed the effectiveness of the use of 455 
collaborative, intense inpatient rehabilitation for individuals with PD. One observational study 456 
found that individuals who participated in an inpatient rehabilitation program post-DBS 457 
placement had expedited optimization of their DBS settings and medications due to the 24-hour 458 
monitoring, reducing the process from a period of months to a period of weeks.  The intense 459 
therapy post-surgery also allowed functional changes and gains to be immediately utilized, 460 
balance and gait training optimized, psychological changes to be monitored, and a home 461 
exercise program to be created to hopefully maintain gains [199].  462 
Ellis et al.[200] further suggests that the comprehensive, multidisciplinary environment 463 
might be effective for individuals with PD who are experiencing a decline in function, falling 464 
more frequently, or are having more complex symptoms. After an average of 21 days of rehab, 465 
71% of the patients in this cohort, including patients who did and did not require medication 466 
alterations, showed a clinically important improvement according to the Functional 467 
Independence Measure [200]. The inpatient rehabilitation team has been suggested to include 468 
some combination of neurosurgeons, neurologists, physical therapists, occupational therapists, 469 
speech-language pathologists, nurses, case managers, nutritionists, sexologists, psychiatrists, 470 
and physiatrists, as is necessary for the individual patient [198-200]. As of now, however, no 471 
comparison of outcomes to standard care or cost analysis has been made. Effects on quality of 472 
life, carryover of training into the home environment, long term outcomes after inpatient 473 
rehabilitation, and characteristics of individuals who are most appropriate for inpatient 474 
rehabilitation are still unknown at this time.  475 
 Multidisciplinary care has also been advocated for outpatient settings, though research 476 
is again limited [198].  Utilization of both medication and physical therapy approaches combined 477 
was superior to medication alone [201].  Multidisciplinary care can result in both short-term [202] 478 
and long-term benefits, and can help most individuals to maintain or improve function for up to 479 
three years [203]. 480 
 481 
Remaining Challenges & Future Directions  482 
While there are multiple approaches to the treatment of gait and balance disorders in 483 
PD, and multidisciplinary approaches offer promise for the best overall management of these 484 
conditions, several areas of challenge remain.  One major issue is the fact that many aspects of 485 
gait and balance are unresponsive to levodopa and likely represent non-dopaminergic features 486 
of disease.  Freezing of gait is an example of a very disabling symptom that is currently not well 487 
addressed by any approach.  Another area of challenge is that of motor complications, i.e. 488 
dyskinesias and wearing off phenomena, that arise after long-term treatment with levodopa.  In 489 
addition to the lack of effective treatments and the presence of treatment side effects, there is 490 
also challenge related to a lack of medical professionals with the specialized training and 491 
knowledge necessary to deliver the most up to date and evidence-based care for people with 492 
PD.   493 
Future directions for the field of gait and balance management in PD are many and will 494 
likely include a shift from monodisciplinary care, where the focus has been on treating the 495 
symptoms, to a multidisciplinary approach that is patient-centered and focuses not only on 496 
symptoms and impairments but also emphasizes quality of life.  Future work is needed to 497 
develop new medications, advance the targeting and application of DBS, and implement more 498 
uniform and informed approaches to physical rehabilitation using evidence-based guidelines.  499 
Several studies are currently underway that will provide new evidence regarding the 500 
effectiveness of exercise-based approaches in the management of PD and should serve to 501 
inform future care models for individuals with PD.   502 
 503 
EXECUTIVE SUMMARY 504 
 Gait, Balance and Falls in Parkinson Disease 505 
o Gait and balance difficulties are a major problem for people with Parkinson disease. 506 
o Gait is characterized by shuffling steps, decreased trunk rotation, flexed posture, decreased 507 
speed, and in some cases freezing.  508 
o Postural instability is one of the four cardinal features of PD and is associated with increased fall 509 
rates. 510 
o  511 
 Therapeutic Approaches to Management of Gait and Balance Problems 512 
o Medical management of PD has, until relatively recently, focused primarily on pharmacological 513 
approaches but many aspects of gait and balance impairments are not adequately addressed 514 
by medication. 515 
o More recently, deep brain stimulation has been added to the arsenal of treatment tools but 516 
again does not fully address gait and balance issues. 517 
o As such, physical rehabilitation approaches are a key aspect of managing gait and balance in 518 
PD and can include specific gait and balance training, resistance training to improve muscle 519 
strength, as well as prescription of assistive devices and use of external cueing. 520 
o No current treatments effectively deal with all aspects of gait and balance impairments, with 521 
freezing of gait being particularly resistant to treatment. 522 
 523 
 Remaining Challenges and Future Directions 524 
o Multidisciplinary, patient-centered care models are emerging and hold promise for improving 525 
quality of care for individuals with PD. 526 
o Such approaches will become critical in the management of gait and balance in PD using a 527 
combination of medications, surgery, and rehabilitation. 528 
o Management of gait and balance in PD is essential as impairments in gait and balance have a 529 
major impact on quality of life, and quality of life may become the main outcome measure for 530 




1.  Fahn S: Description of Parkinson’s disease as a clinical syndrome.  Annals of the New York 535 
Academy of Science. 991, 1-14 (2003). ** Very informative and easy to understand 536 
overview of the major signs and symptoms of PD.  537 
 538
2. Chade AR, Kasten M, Tanner CM: Nongenetic causes of Parkinson's disease. J. Neural 539 
Transm. 70: 147-151 (2006). 540 
 541 
3. Biskup S, Gerlach M, Kupsch A, et al.: Genes associated with Parkinson syndrome. J. 542 
Neurol. 255, 8-17 (2008). 543 
 544 
4. Taylor KS, Cook JA, Counsell CE: Heterogeneity in male to female risk for Parkinson's 545 
disease. J Neurol. Neurosurg. Psychiatry 78, 905-906 (2007). 546 
 547 
5. Spillman BC, Lubitz J:  New estimates of lifetime nursing home use: have patterns of use 548 
changed?  Med. Care. 40, 965-975 (2002). 549 
 550 
6. Perry, EK, et al.: Topography, extent, and clinical relevance of neurochemical deficits in 551 
dementia of Lewy body type, Parkinson’s disease, and Alzheimer’s disease.  Annals of the New 552 
York Academy of Science. 640, 197-202 (1991). 553 
 554
7.  Bloem BR, Hausdorff JM, Visser JE, et al.: Falls and freezing of gait in Parkinson's disease: 555 
a review of two interconnected, episodic phenomena. Mov. Disord. 19(8), 871-884 (2004). ** 556 
Includes excellent model of how gait and balance impairments are part of a vicious cycle 557 
that includes falling and reduced quality of life. 558 
 559 
8. Morris ME, Iansek R, Matyas TA et al.: Ability to modulate walking cadence remains intact in 560 
Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry. 57(12), 1532-4 561 
(1994). 562 
 563 
9. Morris ME, Iansek R, Matyas TA et al.: The pathogenesis of gait hypokinesia in Parkinson’s 564 
disease. Brain. 117(Pt.5), 1169-1181 (1994). 565 
 566 
10. Morris ME, Iansek R, Matyas TA, et al: Stride length regulation in Parkinson’s disease: 567 
normalization strategies and underlying mechanisms. Brain. 119, 551-568 (1996). 568 
 569 
11. Morris ME, McGinley J, Huxham F, et al: Constraints on the kinetic, kinematic, and 570 
spatiotemporal parameters of gait in Parkinson’s disease.  Hum. Mov. Sci., 18, 461-483 (1999). 571 
 572 
12. Morris ME, Huxham FE, McGinley J, et al.: Gait disorders and gait rehabilitation in 573 
Parkinson’s disease.  Adv. Neurol., 87, 347-361 (2001). 574 
 575 
13. Pedersen SW, Öberg B, Larsson LE, et al.:  Gait analysis, isokinetic muscle strength 576 
measurement in patients with Parkinson’s disease.  Scand. J. Rehab. Med. 29, 67-74 (1997).   577 
 578 
14. Rogers MW.  Disorders of posture, balance, and gait in Parkinson’s disease.  Clin. Geriatr. 579 
Med. 12, 825-845 (1996). 580 
 581 
15. Lewis GN, Byblow WD, Walt SE. Stride length regulation in Parkinson’s disease: the use of 582 
extrinsic, visual cues. Brain. 123(Pt. 10), 2077-2090, (2000). 583 
16. Grasso R, Peppe A, Stratta F, et al.: Basal ganglia and gait control: apomorphine 584 
administration and internal pallidum stimulation in Parkinson’s disease. Exp. Brain Res. 126(2), 585 
139-148, (1999). 586 
 587 
17. Steiger MJ, Thompson PD, Marsden CD. Disordered axial movement in Parkinson’s 588 
disease. J. Neurol. Neurosurg. Psychiatry. 61(6), 645-648, (1996). 589 
 590 
18. Camicioli R, Oken BS, Sexton G, et al.: Verbal fluency task affects gait in Parkinson's 591 
disease with motor freezing. J. Geriatr. Psychiatry Neurol.11(4), 181-185, (1998). 592 
 593 
19. O'Shea S, Morris ME, Iansek R. Dual task interference during gait in people with Parkinson 594 
disease: effects of motor versus cognitive secondary tasks. Phys. Ther. 82(9), 888-897 (2002). 595 
 596 
20. Rochester L, Hetherington V, Jones D, et al.: Attending to the task: interference effects of 597 
functional tasks on walking in Parkinson's disease and the roles of cognition, depression, 598 
fatigue, and balance. Arch. Phys. Med. Rehabil. 85(10), 1578-1585 (2004). 599 
  600 
21. Rochester L, Hetherington V, Jones D, et al.: The effect of external rhythmic cues (auditory 601 
and visual) on walking during a functional task in homes of people with Parkinson's disease. 602 
Arch. Phys. Med. Rehabil. 86(5), 999-1006 (2005). 603 
 604 
22. Rochester L, Nieuwboer A, Baker K, et al.:The attentional cost of external rhythmical cues 605 
and their impact on gait in Parkinson's disease: effect of cue modality and task complexity. J. 606 
Neural Transm. 114(10), 1243-1248 (2007).  607 
 608 
23. Plotnik M, Giladi N, Hausdorff JM.  Bilateral coordination of gait and Parkinson's disease: 609 
the effects of dual tasking. J. Neurol. Neurosurg. Psychiatry. 80(3), 347-50 (2009). 610 
 611 
24. Hackney M, Earhart GM.  Backward walking in Parkinson disease. Mov. Disord. 24(2), 218-612 
223 (2009). 613 
 614 
25. Hackney ME, Earhart GM.  The effects of a secondary task on forward and backward 615 
walking in Parkinson disease.  Neurorehabil. Neural Repair, in press. 616 
 617 
26. Morris ME, Huxham F, McGinley J et al.: The biomechanics and motor control of gait in 618 
Parkinson disease. Clinical Biomechanics. 16(6) 459-470 (2001). 619 
*  Good description of gait in PD and effects of medication. 620 
 621 
27. Stack EL, Ashburn Am, Jupp KE: Strategies used by people with Parkinson’s disease who 622 
report difficulty turning. Parkinsonism Relat. Disord. 12, 87-92 (2006). 623 
 624 
28. Crenna P, Carpinella I, Rabuffetti M, et al.:  The association between impaired turning and 625 
normal straight walking in Parkinson’s disease.  Gait & Posture. 26, 172-178 (2006). 626 
  627 
29. Visser JE, Voermans NC, Oude Nijhuis LB, et al.:  Quantification of trunk rotations during 628 
turning and walking in Parkinson’s disease.  Clin. Neurophysiol. 118, 1602-1606 (2007). 629 
 630 
30. Hong M, Perlmutter JS, Earhart GM: A kinematic and electromyographic analysis of turning 631 
in people with Parkinson disease.  Neurorehabil. Neural Repair. 23(2), 166-176 (2009).  632 
 633 
31. Nieuwboer A, Dom R, De Weerdt W, et al.:  Abnormalitites of the spatiotemporal 634 
characteristics of gait at the onset of freezing in Parkinson’s disease.  Mov. Disord. 16, 1066-635 
1075 (2001). 636 
  637 
32. Giladi N, Nieuwboer A: Understanding and treating freezing of gait in parkinsonism, 638 
proposed working definition, and setting the stage. Mov. Disord. 23, S423-S425 (2008). 639 
 640 
33. Michałowska M, Fiszer U, Krygowska-Wajs A, et al.: Falls in Parkinson's disease. Causes 641 
and impact on patients' quality of life. Funct. Neurol. 20(4), 163-8 (2005). 642 
 643 
34. Robinson K, Dennison A, Roalf D, et al.: Falling risk factors in Parkinson's disease. 644 
NeuroRehabilitation. 20(3), 169-82 (2005). 645 
 646 
35. Moore ST, MacDougall HG, Ondo WG:  Ambulatory monitoring of freezing of gait in 647 
Parkinson’s disease. J Neurosci Methods, 167, 340-348 (2008). 648 
 649 
36. Cumming R, Klineberg R: Fall frequency and characteristics and the risk of hip fractures. J. 650 
Am. Ger. Soc.  42, 774-778 (1994). 651 
 652 
37. Benatru I, Vaugoyeau M, Azulay JP:Postural disorders in Parkinson's disease. 653 
Neurophysiologie Clinique. 38(6), 459-465 (2008).  654 
 655 
38. Chastan N, Debono B, Maltete D, Weber J:Discordance between measured postural 656 
instability and absence of clinical symptoms in Parkinson's disease patients in the early stages 657 
of the disease. Movement Disorders. 23(3), 366-372 (2008).  658 
 659 
39. Frenklach A, Louie S, Koop MM, Bronte-Stewart H:Excessive postural sway and the risk of 660 
falls at different stages of Parkinson's disease. Movement Disorders. 24(3), 377-385 (2009).  661 
 662 
40. Mancini M, Zampieri C, Carlson-Kuhta P, Chiari L, Horak FB:Anticipatory postural 663 
adjustments prior to step initiation are hypometric in untreated Parkinson's disease: an 664 
accelerometer-based approach. European Journal of Neurology. 16(9), 1028-1034 (2009).  665 
 666 
41. Grimbergen YA, Langston JW, Roos RA, Bloem BR:Postural instability in Parkinson's 667 
disease: the adrenergic hypothesis and the locus coeruleus. Expert Review of 668 
Neurotherapeutics. 9(2), 279-290 (2009).  669 
 670 
42. Horak FB, Dimitrova D, Nutt JG:Direction-specific postural instability in subjects with 671 
Parkinson's disease. Exp. Neurol. 193(2), 504-521 (2005).  672 
 673 
43. Kerr GK, Worringham CJ, Cole MH, Lacherez PF, Wood JM, Silburn PA:Predictors of future 674 
falls in Parkinson disease. Neurology. 75(2), 116-124 (2010).  675 
 676 
44. Kim S, Horak FB, Carlson-Kuhta P, Park S:Postural feedback scaling deficits in Parkinson's 677 
disease. J. Neurophysiol. 102(5), 2910-2920 (2009).  678 
 679 
45. King LA, St George RJ, Carlson-Kuhta P, Nutt JG, Horak FB:Preparation for Compensatory 680 
Forward Stepping in Parkinson's Disease. Arch. Phys. Med. Rehabil. 91(9), 1332-1338 (2010).  681 
 682 
46. McVey MA, Stylianou AP, Luchies CW, et al.:Early biomechanical markers of postural 683 
instability in Parkinson's disease. Gait Posture. 30(4), 538-542 (2009).  684 
47. Grimbergen YA, Munneke M, Bloem BR. Falls in Parkinson’s disease. Curr. Opin. Neurol. 685 
17(4), 405-415, (2004). 686 
 687 
48. Bohnen NI, Cham R:Postural control, gait, and dopamine functions in parkinsonian 688 
movement disorders. Clin. Geriatr. Med. 22(4), 797-812, vi (2006).  689 
 690 
49. Visser M, Marinus J, Bloem BR, Kisjes H, van den Berg BM, van Hilten JJ:Clinical tests for 691 
the evaluation of postural instability in patients with parkinson's disease. Arch. Phys. Med. 692 
Rehabil. 84(11), 1669-1674 (2003).  693 
 694 
50. Valkovic P, Brozova H, Botzel K, Ruzicka E, Benetin J:Push-and-release test predicts 695 
Parkinson fallers and nonfallers better than the pull test: comparison in OFF and ON medication 696 
states. Mov. Disord. 23(10), 1453-1457 (2008).  697 
 698 
51. Blaszczyk JW, Orawiec R, Duda-Klodowska D, Opala G:Assessment of postural instability 699 
in patients with Parkinson's disease. Exp. Brain Res. 183(1), 107-114 (2007).  700 
 701 
52. Buckley TA, Pitsikoulis C, Hass CJ:Dynamic postural stability during sit-to-walk transitions in 702 
Parkinson disease patients. Mov. Disord. 23(9), 1274-1280 (2008).  703 
 704 
53. Merello M, Fantacone N, Balej J:Kinematic study of whole body center of mass position 705 
during gait in Parkinson's disease patients with and without festination. Mov. Disord. 25(6), 739-706 
746 (2010).  707 
 708 
54. Bleuse S, Cassim F, Blatt JL, et al.:Anticipatory postural adjustments associated with arm 709 
movement in Parkinson's disease: a biomechanical analysis. J. Neurol. Neurosurg. Psychiatry. 710 
79(8), 881-887 (2008).  711 
 712 
55. Dimitrova D, Horak FB, Nutt JG:Postural muscle responses to multidirectional translations in 713 
patients with Parkinson's disease. J. Neurophysiol. 91(1), 489-501 (2004).  714 
 715 
56. Adkin AL, Frank JS, Jog MS:Fear of falling and postural control in Parkinson's disease. Mov. 716 
Disord. 18(5), 496-502 (2003).  717 
 718 
57. Ashburn A, Fazakarley L, Ballinger C, Pickering R, McLellan LD, Fitton C:A randomised 719 
controlled trial of a home based exercise programme to reduce the risk of falling among people 720 
with Parkinson's disease. Journal of Neurology, Neurosurgery & Psychiatry. 78(7), 678-684 721 
(2007).  722 
 723 
58. Latt MD, Lord SR, Morris JG, Fung VS:Clinical and physiological assessments for 724 
elucidating falls risk in Parkinson's disease. Mov. Disord. 24(9), 1280-1289 (2009).  725 
 726 
59. Matinolli M, Korpelainen JT, Korpelainen R, Sotaniemi KA, Virranniemi M, Myllyla 727 
VV:Postural sway and falls in Parkinson's disease: a regression approach. Mov. Disord. 22(13), 728 
1927-1935 (2007).  729 
 730 
60. Bloem BR, Grimbergen YA, Cramer M, Willemsen M, Zwinderman AH:Prospective 731 
assessment of falls in Parkinson's disease. J. Neurol. 248(11), 950-958 (2001).  732 
 733 
61. Fink HA, Kuskowski MA, Orwoll ES, Cauley JA, Ensrud KE, Osteoporotic Fractures in Men 734 
(MrOS) Study Group:Association between Parkinson's disease and low bone density and falls in 735 
older men: the osteoporotic fractures in men study. J. Am. Geriatr. Soc. 53(9), 1559-1564 736 
(2005).  737 
 738 
62. Temlett JA, Thompson PD:Reasons for admission to hospital for Parkinson’s disease.  739 
Intern. Med. J. 36(8), 524-526 (2006).  740 
 741 
63. Woodford H, Walker R:Emergency hospital admissions in idiopathic Parkinson's disease. 742 
Movement Disorders. 20(9), 1104-1108 (2005).  743 
 744 
64. Allcock LM, Rowan EN, Steen IN, Wesnes K, Kenny RA, Burn DJ:Impaired attention 745 
predicts falling in Parkinson's disease. Parkinsonism Relat. Disord. 15(2), 110-115 (2009).  746 
 747 
65. Ashburn A, Stack E, Ballinger C, Fazakarley L, Fitton C:The circumstances of falls among 748 
people with Parkinson's disease and the use of Falls Diaries to facilitate reporting. Disabil. 749 
Rehabil. 30(16), 1205-1212 (2008).  750 
 751 
66. Wood BH, Bilclough JA, Bowron A, Walker RW:Incidence and prediction of falls in 752 
Parkinson's disease: a prospective multidisciplinary study. J. Neurol. Neurosurg. Psychiatry. 753 
72(6), 721-725 (2002).  754 
 755 
67. Melton LJ III, Leibson CL, Achenbach SJ, Bower JH, Maraganore DM, Ober AL, Rocca WA. 756 
Fracture risk after the diagnosis of Parkinson’s disease: influence of concomitant dementia. Mov 757 
Disord, 21(9): 1361-1367, 2006. 758 
 759 
68. Rahman S, Griffin HJ, Quinn NP, Jahanshahi M:Quality of life in Parkinson's disease: The 760 
relative importance of the symptoms. Movement Disorders. 23(10), 1428-1434 (2008).  761 
 762 
69. Bacon WE: Secular trends in hip fracture occurrence and survival: age and sex differences. 763 
J. Aging Health. 8(4), 538-553 (1996).  764 
 765 
70. Kempster PA, O'Sullivan SS, Holton JL, Revesz T, Lees AJ:Relationships between age and 766 
late progression of Parkinson's disease: a clinico-pathological study. Brain. 133(Pt 6), 1755-767 
1762 (2010).  768 
 769 
71. Dennison AC, Noorigian JV, Robinson KM, et al.:Falling in Parkinson disease: identifying 770 
and prioritizing risk factors in recurrent fallers. Am. J. Phys. Med. Rehabil. 86(8), 621-632 771 
(2007).  772 
 773 
72. Mak MK, Pang MY:Fear of falling is independently associated with recurrent falls in patients 774 
with Parkinson's disease: a 1-year prospective study. J. Neurol. 256(10), 1689-1695 (2009).  775 
 776 
73. Martignoni E, Tassorelli C, Nappi G:Cardiovascular dysautonomia as a cause of falls in 777 
Parkinson's disease. Parkinsonism Relat. Disord. 12(4), 195-204 (2006).  778 
 779 
74. Moore ST, MacDougall HG, Gracies JM et al.: Locomotor response to levodopa in 780 
fluctuating Parkinson’s Disease. Experimental Brain Research. 184(4), 469-478 (2008). 781 
 782 
75. Sethi K.: Levodopa unresponsive symptoms in Parkinson disease. Movement Disorders. 783 
23(Suppl 3), S521-S533 (2008). 784 
 785 
76. Blin O, Fernandez AM, Pailhous J et al.: Dopa-sensitive and dopa-resistance gait 786 
parameters in Parkinson’s disease. Journal of the Neurological Sciences. 103(1), 51-4 (1991). 787 
 788 
77. Blin O, Fernandez AM, Serratrice G.: Quantitative analysis of gait in Parkinson patients: 789 
increased variability of stride length. Journal of the Neurological Sciences. 98(1), 91-7 (1990). 790 
 791 
78. Bowes SG, Clark PK, Leeman AL et al.: Determinants of gait in the elderly parkinsonian on 792 
maintenance levodopa/carbidopa therapy. British Journal of Clinical Pharmacology. 30(1), 13-24 793 
(1990). 794 
 795 
79. Pedersen SW, Eriksson T, Oberg B. Effects of withdrawal of antiparkinson medication on 796 
gait and clinical score in the Parkinson patient. Acta Neurologica Scandinavica. 84(1), 7-13 797 
(1991). 798 
 799 
80. McIntosh GC, Brown SH, Rice RR et al.: Rhythmic auditory-motor facilitation of gait patterns 800 
in patients with Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry. 62(1), 801 
22-6 (1997). 802 
 803 
81. Azulay JP, Mesure S, Amblard B et al.: Visual control of locomotion in Parkinson’s disease. 804 
Brain. 122(Pt.1), 111-120 (1999). 805 
 806 
82. Hanakawa T, Katsumi Y, Fukuyama H et al.: Enhanced lateral premotor activity during 807 
paradoxical gait in Parkinson’s disease. Annals of Neurology. 45(3), 329-336 (1999). 808 
 809 
83. Ebersbach G, Sojer M, Valldeoriola F et al.: Comparative analysis of gait in Parkinson’s 810 
disease, cerebellar ataxia and subcortical arteriosclerotic encephalopathy. Brain. 122(Pt.7) 811 
1349-1355 (1999). 812 
 813 
84. Morris ME, Matyas TA, Iansek R et al.: Temporal stability of gait in Parkinson’s disease. 814 
Physical Therapy. 76(7), 763-777 (1996). 815 
 816 
85. Koozekanani SH, Balmaseda MT Jr, Fatehi MT et al.: Ground reaction forces during 817 
ambulation in parkinsonism: pilot study. Archives of Physical Medicine & Rehabilitation. 68(1), 818 
28-30 (1987). 819 
 820 
86. O’Sullivan JD, Said CM, Dillon LC et al.: Gait analysis in patients with Parkinson’s disease 821 
and motor fluctuations: influence of levodopa and comparison with other measures of motor 822 
function. Movement Disorders. 13(6), 900-6 (1998). 823 
 824 
87. Morris M, Iansek R, Matyas T et al.: Abnormalities in the stride length-cadence relation in 825 
parkinsonian gait. Movement Disorders. 13(1), 61-9 (1998). 826 
 827 
88. Okuma Y.: Freezing of gait in Parkinson’s disease. Journal of Neurology. 253(Suppl 7), 828 
VII27-32 (2006). 829 
 830 
89. Fahn S.: The freezing phenomenon in parkinsonism. Advances in Neurology. 67, 53-63 831 
(1995). 832 
 833 
90. Schaafsma JD, Balash Y, Gurevich T et al.: Characterization of freezing of gait subtypes 834 
and the response of each to levodopa in Parkinson’s disease. European Journal of Neurology. 835 
10(4), 391-8 (2003). 836 
 837 
91. Giladi N.: Freezing of gait. Clinical overview. Advances in Neurology. 87, 191-7 (2001). 838 
 839 
92. Giladi N.: Medical treatment of freezing of gait. Movement Disorders. 23 (Suppl 2), S482-8 840 
(2008). 841 
 842 
93. Giladi N, McDermott MP, Fahn S et al.: Freezing of gait in PD: prospective assessment in 843 
the DATATOP cohort. Neurology. 56(12), 1712-1721 (2001). 844 
 845 
94. Shoulson I.: DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. 846 
Deprenyl and tocopherol antioxidative therapy of parkinsonism. Annals of Neurology. 44(3 847 
Suppl 1), S160-6 (1998). 848 
 849 
95. Shoulson I, Oakes D, Fahn S et al.: Impact of sustained deprenyl (selegiline) in levodopa-850 
treated Parkinson’s disease: a randomized placebo-controlled extension of the deprenyl and 851 
tocopherol antioxidative therapy of parkinsonism trial. Annals of Neurology. 51(5), 604-612 852 
(2002). 853 
 854 
96. Giladi N, Treves TA, Simon ES et al.: Freezing of gait in patients with advances Parkinson’s 855 
disease. Journal of Neural Transmission. 108(1), 53-61 (2001). 856 
 857 
97. Macht M, Kaussner Y, Moller JC et al.: Predictors of freezing in Parkinson’s disease: a 858 
survey of 6,620 patients. Movement Disorders. 22(7), 953-6 (2007). 859 
 860 
98. Giladi N and Honigman S.: Botulinum toxin injections to one leg alleviate freezing of gait in a 861 
patient with Parkinson’s disease. Movement Disorders. 12(6), 1085-6 (1997). 862 
 863 
99. Giladi N, Gurevich T, Shabtai H et al.: The effect of botulinum toxin injections to the calf 864 
muscles on freezing of gait in parkinsonism: a pilot study. Journal of Neurology. 248(7), 572-6 865 
(2001). 866 
 867 
100. Gurevich T, Peretz C, Moore O et al.: The effect of injecting botulinum toxin type a into the 868 
calf muscles on freezing of gait in Parkinson’s disease: a double blind placebo-controlled pilot 869 
study. Movement Disorders. 22(6), 880-3 (2007). 870 
 871 
101. Pollak L, Dobronevsky Y, Prohorov T et al.: Low dose methylphenidate improves freezing 872 
in advanced Parkinson’s disease during off-state. Journal of Neural Transmission 873 
Supplementum. 72, 145-8 (2007). 874 
 875 
102. Auriel E, Hausdorff JM, Herman T et al.: Effects of methylphenidate on cognitive function 876 
and gait in patients with Parkinson’s disease: a pilot study. Clinical Neuropharmacology. 29(1), 877 
15-7 (2006). 878 
 879 
103. Vaamonde Gamo J, Cabello JP, Gallardo Alcañiz MJ, et al.: Freezing of gait unresponsive 880 
to dopaminergic stimulation in patients with severe Parkinsonism.   Neurologia. 25(1), 27-31 881 
(2010). 882 
  883 
104. Clarke CE, Worth P, Grosset D et al.: Systematic review of apomorphine infusion, 884 
levodopa infusion and deep brain stimulation in advanced Parkinson’s disease. Parkinsonism & 885 
Related Disorders. 15(10), 728-741 (2009). 886 
 887 
105. Tagliati M. Fine-tuning gait in Parkinson disease. Neurology. 71(2), 76-7 (2008). 888 
 889 
106. Van Nuenen BF, Esselink RA, Munneke M et al.: Postoperative gait deterioration after 890 
bilateral subthalamic nucleus stimulation in Parkinson’s disease. Movement Disorders. 23(16), 891 
2404-6 (2008). 892 
 893 
107. Krack P, Batir A, Blercom N et al.: Five-year follow-up of bilateral stimulation of the 894 
subthalamic nucleus in advanced Parkinson’s disease. The New England Journal of Medicine. 895 
349(20), 1925-1934 (2003). 896 
 897 
108. Bakker M, Esselink RA, Munneke M et al.: Effects of stereotactic neurosurgery on postural 898 
instability and gait in Parkinson’s disease. Movement Disorders. 19(9), 1092-9 (2004). 899 
 900 
109. Johnsen EL, Mogensen PH, Sunde NA et al.: Improved asymmetry of gait in Parkinson’s 901 
disease with DBS: gait and postural instability in Parkinson’s disease treated with bilateral 902 
stimulation in the subthalamic nucleus. Movement Disorders. 24(4), 590-7 (2009). 903 
 904 
110. Hausdorff JM, Gruendlinger L, Scollins L et al.: Deep brain stimulation effects on gait 905 
variability in Parkinson’s disease. Movement Disorders. 24(11), 1688-1692 (2009). 906 
 907 
111. Volkmann J.: Deep brain stimulation for the treatment of Parkinson’s disease. Journal of 908 
Clinical Neurophysiology. 21(1), 6-17 (2004). 909 
 910 
112. Mazzone P, Lozano A, Stanzione P et al.: Implantation of human pedunculopontine 911 
nucleus: a safe and clinically relevant target in Parkinson’s disease. Neuroreport. 16(17), 1877-912 
1881 (2005). 913 
 914 
113. Plaha P and Gill SS.: Bilateral deep brain stimulation of the pedunculopontine nucleus for 915 
Parkinson’s disease. Neuroreport. 16(17), 1883-7 (2005). 916 
 917 
114. Moro E, Hamani C, Poon YY et al.: Unilateral pedunculopontine stimulation improves fall in 918 
Parkinson’s disease. Brain. 133(Pt.1), 215-224 (2010). 919 
 920 
115. Stefani A, Lozano AM, Peppe A et al.: Bilateral deep brain stimulation of the 921 
pedunculopontine and subthalamic nuclei in severe Parkinson’s disease. Brain. 130(Pt.6), 1596-922 
1607 (2007). 923 
 924 
116. Davis JT, Lyons KE, Pahwa R.: Freezing of gait after bilateral subthalamic nucleus 925 
stimulation for Parkinson’s disease. Clinical Neurology and Neurosurgery. 108(5), 461-4 (2006). 926 
 927 
117. Limousin P, Krack P, Pollak P et al.: Electrical stimulation of the subthalamic nucleus in 928 
advanced Parkinson’s disease. The New England Journal of Medicine. 339(16), 1105-1111 929 
(1998). 930 
 931 
118. Stolze H, Klebe S, Poepping M et al.: Effects of bilateral subthalamic nucleus stimulation 932 
on parkinsonian gait. Neurology. 57(1), 144-6 (2001). 933 
 934 
119. Yokoyama T, Sugiyama K, Nishizawa S et al.: Subthalamic nucleus stimulation for gait 935 
disturbance in Parkinson’s disease. Neurosurgery. 45(1), 41-7 (1999). 936 
 937 
120. Rodriguez-Oroz MC, Obeso JA, Lang AE et al.: Bilateral deep brain stimulation in 938 
Parkinson’s disease: a multicentre study with 4 years follow-up. Brain. 128(Pt.10), 2240-9 939 
(2005). 940 
 941 
121. Bejjani BP, Gervais D, Arnulf I et al.: Axial parkinsonian symptoms can be improved: the 942 
role of levodopa and bilateral subthalamic stimulation. Journal of Neurology, Neurosurgery and 943 
Psychiatry. 68(5), 595-600 (2000) 944 
 945 
122. Nandi D, Aziz TZ, Giladi N et al.: Reversal of akinesia in experimental parkinsonism by 946 
GABA antagonist microinjections in the pedunculopontine nucleus. Brain. 125(Pt.11), 2418-947 
2430 (2002). 948 
 949 
123. Munro-Davies LE, Winter J, Aziz TZ et al.: The role of the pedunculopontine region in 950 
basal-ganglia mechanisms of akinesia. Experimental Brain Research. 129(4), 511-7 (1999). 951 
 952 
124. Benedetti F, Pollo A, Lopiano L et al.: Conscioius expectation and unconscious 953 
conditioning in analgesic, motor, and hormonal placebo/nocebo responses. The Journal of 954 
Neuroscience. 23(10), 4315-4323 (2003). 955 
 956 
125. Mehrholz J, Friis R, Kugler J et al.: Treadmill training for patients with Parkinson’s disease 957 
(Review). Cochrane Database Systematic Review. (1), 1-31 (2010). 958 
 959 
126. Fisher BE, Wu AD, Salem GJ et al.: The effect of exercise training in improving motor 960 
performance and corticomotor excitability in people with early Parkinson’s disease. Archives of 961 
Physical Medicine & Rehabilitation. 89(7), 1221-9 (2008). 962 
 963 
127. Pohl M, Rockstroh G, Ruckriem S et al.: Immediate effects of speed-dependent treadmill 964 
training on gait parameters in early Parkinson’s disease. Archives of Physical Medicine and 965 
Rehabilitation. 84(12), 1760-6 (2003). 966 
 967 
128. Miyai I, Fujimoto Y, Ueda Y et al.: Treadmill training with body weight support: its effect on 968 
Parkinson’s disease. Archives of Physical Medicine and Rehabilitation. 81(7), 849-852 (2000). 969 
 970 
129. Protas EJ, Mitchell K, Williams A et al. Gait and step training to reduce falls in Parkinson’s 971 
disease. NeuroRehabilitation. 20(3), 183-190 (2005). 972 
 973 
130. Cakit BD, Saracoglu M, Genc H et al.: The effects of incremental speed-dependent 974 
treadmill training on postural instability and fear of falling in Parkinson’s disease. Clinical 975 
Rehabilitation. 21(8), 698-705 (2007). 976 
 977 
131. Kurtais Y, Kutlay S, Tur BS et al.: Does treadmill training improve lower-extremity tasks in 978 
Parkinson disease? A randomized controlled trial. Clinical Journal of Sports Medicine. 18(3), 979 
289-291 (2008). 980 
 981 
132. Herman T, Giladi N, Gruendlinger L et al.: Six weeks of intensive treadmill training 982 
improves gait and quality of life in patients with Parkinson’s disease: A pilot study. Archives of 983 
Physical Medicine and Rehabilitation. 88(9), 1154-8 (2007). 984 
 985 
133. Bello O, Marquez G, Camblor M et al.: Mechanisms involved in treadmill walking 986 
improvements in Parkinson’s disease. Gait and Posture. 32, 118-123 (2010).  987 
 988 
134. Rubinstein TC, Giladi N, Hausdorff JM.: The power of cueing to circumvent dopamine 989 
deficits: a review of physical therapy treatment of gait disturbances in Parkinson’s disease. 990 
Movement Disorders. 17(6), 1148-1160 (2002). 991 
 992 
135. Murray MP, Sepic SB, Gardner GM et al.: Walking patterns of men with parkinsonism. 993 
American Journal of Physical Medicine. 57(6), 278-294 (1978). 994 
 995 
136. Morris ME.: Movement disorders in people with Parkinson disease: a model for physical 996 
therapy. Physical Therapy. 80(6), 578-597 (2000). 997 
 998 
137. Rochester L, Baker K, Hetherington V, et al.:Evidence for motor learning in Parkinson's 999 
disease: acquisition, automaticity and retention of cued gait performance after training with 1000 
external rhythmical cues. Brain Res. 1319 103-111 (2010).  1001 
 1002 
138. Jiang Y, Norman KE:Effects of visual and auditory cues on gait initiation in people with 1003 
Parkinson's disease. Clin. Rehabil. 20(1), 36-45 (2006).  1004 
 1005 
139. Rochester L, Burn DJ, Woods G, Godwin J, Nieuwboer A:Does auditory rhythmical cueing 1006 
improve gait in people with Parkinson's disease and cognitive impairment? A Feasibility study. 1007 
Movement Disorders. 24(6), 839-845 (2009).  1008 
 1009 
140. Suteerawattananon M, Morris GS, Etnyre BR, Jankovic J, Protas EJ:Effects of visual and 1010 
auditory cues on gait in individuals with Parkinson's disease. J. Neurol. Sci. 219(1-2), 63-69 1011 
(2004).  1012 
 1013 
141. Willems AM, Nieuwboer A, Chavret F, et al.:Turning in Parkinson's disease patients and 1014 
controls: the effect of auditory cues. Mov. Disord. 22(13), 1871-1878 (2007).  1015 
 1016 
142. Nieuwboer A, Baker K, Willems AM, et al.:The short-term effects of different cueing 1017 
modalities on turn speed in people with Parkinson's disease. Neurorehabil. Neural Repair. 1018 
23(8), 831-836 (2009).  1019 
 1020 
143. Rochester L, Rafferty D, Dotchin C, Msuya O, Minde V, Walker RW:The effect of cueing 1021 
therapy on single and dual-task gait in a drug naive population of people with Parkinson's 1022 
disease in northern Tanzania. Mov. Disord. 25(7), 906-911 (2010).  1023 
 1024 
144. Mak MK, Hui-Chan CW:Cued task-specific training is better than exercise in improving sit-1025 
to-stand in patients with Parkinson's disease: A randomized controlled trial. Mov. Disord. 23(4), 1026 
501-509 (2008).  1027 
 1028 
145. Baker K, Rochester L, Nieuwboer A:The effect of cues on gait variability--reducing the 1029 
attentional cost of walking in people with Parkinson's disease. Parkinsonism Relat. Disord. 1030 
14(4), 314-320 (2008).  1031 
 1032 
146. Baker K, Rochester L, Nieuwboer A:The Immediate Effect of Attentional, Auditory, and a 1033 
Combined Cue Strategy on Gait During Single and Dual Tasks in Parkinson’s Disease. Arch. 1034 
Phys. Med. Rehabil. 88(12), 1593-1600 (2007).  1035 
 1036 
147. Nieuwboer A: Cueing for freezing of gait in patients with Parkinson's disease: a 1037 
rehabilitation perspective. Mov. Disord. 23 Suppl 2 S475-81 (2008).  1038 
 1039 
148. Bryant MS, Rintala DH, Lai EC, Protas EJ:An evaluation of self-administration of auditory 1040 
cueing to improve gait in people with Parkinson's disease. Clin. Rehabil. 23(12), 1078-1085 1041 
(2009).  1042 
 1043 
149. Morris ME, Martin CL, Schenkman ML:Striding out with Parkinson disease: evidence-1044 
based physical therapy for gait disorders. Phys. Ther. 90(2), 280-288 (2010). 1045 
* Review of current evidence to support specific physical therapy approaches to 1046 
management of gait in PD.  1047 
 1048 
150. Satoh M, Kuzuhara S:Training in mental singing while walking improves gait disturbance in 1049 
Parkinson's disease patients. Eur. Neurol. 60(5), 237-243 (2008).  1050 
 1051 
151. Ford MP, Malone LA, Nyikos I, Yelisetty R, Bickel CS:Gait training with progressive 1052 
external auditory cueing in persons with Parkinson's disease. Arch. Phys. Med. Rehabil. 91(8), 1053 
1255-1261 (2010).  1054 
 1055 
152. Nieuwboer A, Kwakkel G, Rochester L, et al.: Cueing training in the home improves gait-1056 
related mobility in Parkinson's disease: the RESCUE trial.  J. Neurol. Neurosurg. Psychiatry. 1057 
78(2), 134-140, (2007). 1058 
 1059 
153. Bryant MS, Rintala DH, Lai EC, et al.: Evaluation of a new device to prevent falls in 1060 
persons with Parkinson's disease.Disabil Rehabil Assist Technol. 4(5), 357-63 (2010). 1061 
  1062 
154. Cubo E, Moore CG, Leugran S, et al.: Wheeled and standard walkers in Parkinson's 1063 
disease patients with gait freezing.Parkinsonism Relat. Disord. 10(1), 9-14 (2003).  1064 
 1065 
155. Constantinescu R, Leonard C, Deeley C, et al.: Assistive devices for gait in Parkinson's 1066 
disease. Parkinsonism Relat. Disord.13(3), 133-8 (2007).  1067 
 1068 
156. Bächlin M, Plotnik M, Roggen D, et al.: A wearable system to assist walking of Parkinson s 1069 
disease patients.Methods Inf. Med. 49(1), 88-95 (2010).  1070 
 1071 
157. Cano-de-la-Cuerda R, Perez-de-Heredia M, Miangolarra-Page JC et al.: Is there muscular 1072 
weakness in Parkinson’s disease? American Journal of Physical Medicine & Rehabilitation. 1073 
89(1), 70-6 (2010). 1074 
 1075 
158. Koller W and Kase S. Muscle strength testing in Parkinson’s disease. European Neurology. 1076 
25(2), 130-3 (1986). 1077 
 1078 
159. Macaluso A and De Vito G.: Muscle strength, power and adaptations to resistance training 1079 
in older people. European Journal of Applied Physiology. 91(4), 450-472 (2004). 1080 
 1081 
160. Falvo MJ, Schilling BK, Earhart GM.: Parkinson’s disease and resistive exercise: rationale, 1082 
review and recommendations. Movement Disorders.  23(1), 1-11 (2008). 1083 
 1084 
161. Dibble LE, Hale TF, Marcus RL et al.: High intensity eccentric resistance training 1085 
decreases bradykinesia and improves quality of life in persons with Parkinson’s disease: a 1086 
preliminary study. Parkinsonism & Related Disorders. 15(10), 752-7 (2009). 1087 
 1088 
162. Dibble LE, Hale TF, Marcus RL et al.: High-intensity resistance training amplifies muscle 1089 
hypertrophy and functional gains in persons with Parkinson’s disease. Movement Disorders. 1090 
21(9), 1444-1452 (2006). 1091 
 1092 
163. Scandalis TA, Bosak A, Berliner JC et al.: Resistance training and gait function in patients 1093 
with Parkinson’s disease. American Journal of Physical Medicine & Rehabilitation. 80(1), 38-43 1094 
(2001). 1095 
 1096 
164. Hirsch MA, Toole T, Matiland CG et al.: The effects of balance training and high-intensity 1097 
resistance training on persons with idiopathic Parkinson’s disease. Archives of Physical 1098 
Medicine and Rehabilitation. 84(8), 1109-1117 (2003). 1099 
 1100 
165. Toole T, Hirsch MA, Forkink A et al.: The effects of a balance and strength training 1101 
program on equilibrium in Parkinsonism: a preliminary study. NeuroRehabilitation. 14(3), 165-1102 
174 (2000). 1103 
 1104 
166. Dibble LE, Addison O, Papa E:The effects of exercise on balance in persons with 1105 
Parkinson's disease: a systematic review across the disability spectrum. Journal of Neurologic 1106 
Physical Therapy. 33(1), 14-26 (2009). ** Systematic review of latest evidence on balance 1107 
training in PD. 1108 
 1109 
167. Keus SH, Bloem BR, Hendriks EJ, Bredero-Cohen AB, Munneke M, Practice 1110 
Recommendations Development Group:Evidence-based analysis of physical therapy in 1111 
Parkinson's disease with recommendations for practice and research. Mov. Disord. 22(4), 451-1112 
60; quiz 600 (2007).  1113 
** Establishes evidence-based guidelines for physical therapy practice in PD. 1114 
 1115 
168. Canning CG, Sherrington C, Lord SR, et al.:Exercise therapy for prevention of falls in 1116 
people with Parkinson's disease: a protocol for a randomised controlled trial and economic 1117 
evaluation. BMC Neurol. 9 4 (2009).  1118 
 1119 
169. Frazzitta G, Maestri R, Bertotti G, et al.:Rehabilitation in Parkinson's disease: assessing 1120 
the outcome using objective metabolic measurements. Mov. Disord. 25(5), 609-614 (2010).  1121 
 1122 
170. King LA, Horak FB:Delaying mobility disability in people with Parkinson disease using a 1123 
sensorimotor agility exercise program. Phys. Ther. 89(4), 384-393 (2009).  1124 
 1125 
171. Tamir R, Dickstein R, Huberman M:Integration of motor imagery and physical practice in 1126 
group treatment applied to subjects with Parkinson's disease. Neurorehabil. Neural Repair. 1127 
21(1), 68-75 (2007).  1128 
 1129 
172. Gobbi LTB, Oliveira-Ferreira MDT, Caetano MJD, et al.:Exercise programs improve 1130 
mobility and balance in people with Parkinson's disease. Parkinsonism Relat. Disord. 1131 
15(Supplement 3), S49-S52 (2009).  1132 
 1133 
173. Jessop RT, Horowicz C, Dibble LE:Motor learning and Parkinson disease: Refinement of 1134 
movement velocity and endpoint excursion in a limits of stability balance task. Neurorehabil. 1135 
Neural Repair. 20(4), 459-467 (2006).  1136 
 1137 
174. Arias P, Chouza M, Vivas J, Cudeiro J:Effect of whole body vibration in Parkinson's 1138 
disease: A controlled study. Movement Disorders. 24(6), 891-898 (2009).  1139 
 1140 
175. Ebersbach G, Edler D, Kaufhold O, Wissel J:Whole Body Vibration Versus Conventional 1141 
Physiotherapy to Improve Balance and Gait in Parkinson’s Disease. Arch. Phys. Med. Rehabil. 1142 
89(3), 399-403 (2008).  1143 
 1144 
176. Rossi-Izquierdo M, Soto-Varela A, Santos-Perez S, et al.:Vestibular rehabilitation with 1145 
computerised dynamic posturography in patients with Parkinson's disease: improving balance 1146 
impairment. Disability & Rehabilitation. 31(23), 1907-1916 (2009).  1147 
 1148 
177. Zeigelboim BS, Klagenberg KF, Teive HA, Munhoz RP, Martins-Bassetto J:Vestibular 1149 
rehabilitation: clinical benefits to patients with Parkinson's disease. Arq. Neuropsiquiatr. 67(2A), 1150 
219-223 (2009).  1151 
 1152 
178. Winogrodzka A, Wagenaar RC, Booij J, Wolters EC:Rigidity and bradykinesia reduce 1153 
interlimb coordination in Parkinsonian gait. Arch. Phys. Med. Rehabil. 86(2), 183-189 (2005).  1154 
 1155 
179. Wright WG, Gurfinkel VS, Nutt J, Horak FB, Cordo PJ:Axial hypertonicity in Parkinson's 1156 
disease: Direct measurements of trunk and hip torque. Exp. Neurol. 208(1), 38-46 (2007).  1157 
 1158 
180. Schenkman M, Cutson TM, Kuchibhatla M, et al.:Exercise to improve spinal flexibility and 1159 
function for people with Parkinson's disease: a randomized, controlled trial. J. Am. Geriatr. Soc. 1160 
46(10), 1207-1216 (1998).  1161 
 1162 
181. Schenkman M, Morey M, Kuchibhatla M:Spinal flexibility and balance control among 1163 
community-dwelling adults with and without Parkinson's disease. J. Gerontol. A Biol. Sci. Med. 1164 
Sci. 55(8), M441-5 (2000).  1165 
 1166 
182. Franzén E, Paquette C, Gurfinkel VS, Cordo PJ, Nutt JG, Horak FB:Reduced performance 1167 
in balance, walking and turning tasks is associated with increased neck tone in Parkinson's 1168 
disease. Exp. Neurol. 219(2), 430-438 (2009).  1169 
 1170 
183. Bartolo M, Serrao M, Tassorelli C, et al.:Four-week trunk-specific rehabilitation treatment 1171 
improves lateral trunk flexion in Parkinson's disease. Movement Disorders. 25(3), 325-331 1172 
(2010).  1173 
 1174 
184. Palo-Bengtsson L, Ekman SL:  Social dancing in the care of persons with dementia in a 1175 
nursing home setting: a phenomenological study.  Sch. Inq. Nurs. Pract. 11(2), 101-8 (1997). 1176 
 1177 
185. Belardinelli, R et al.: Waltz dancing in patients with chronic heart failure: a new form of 1178 
exercise training.  Circulation: Heart Failure. 1, 107-114 (2008).  1179 
 1180 
186. Peidro RM et al.: Tango: modificaciones cardiorrespiratorias durante el baile.  Revista 1181 
Argentina de Cardiologia, 70, 358-363 (2002). 1182 
 1183 
187. Hackney ME, Kantorovich S, Levin R, et al.: Effects of tango on functional mobility in 1184 
Parkinson disease: A preliminary study. J. Neurol. Phys. Ther. 31(4), 173-179 (2007). 1185 
 1186 
188. Hackney ME, Earhart GM: Short Duration, Intensive Tango Dancing for Parkinson 1187 
Disease: An Uncontrolled Pilot Study. Complement. Ther. Med. 17, 203-207 (2009). 1188 
 1189 
189. Hackney ME, Earhart GM: Effects of dance on movement control in Parkinson disease: a 1190 
comparison of Argentine Tango and American Ballroom. J. Rehab. Med. 41, 475-481 (2009). 1191 
 1192 
190. Hackney ME, Earhart GM: Effects of dance on gait and balance in Parkinson disease: a 1193 
comparison of partnered and non-partnered dance movement. Neurorehabil. Neural Repair. 1194 
24(4), 384-392 (2010).  1195 
 1196 
191. Hackney ME, Earhart GM: Effects of dance on balance and gait in severe Parkinson 1197 
disease: A case study.  Disabil. Rehab. 32(8), 679-684 (2010). 1198 
 1199 
192. Earhart GM:  Dance as therapy for individuals with Parkinson disease. (2009) Eur. J. Phys. 1200 
Med. Rehabil. 45(2), 231-238 (2009). 1201 
 1202 
193. Hackney ME, Earhart GM: Recommendations for implementing partnered tango classes 1203 
for persons with Parkinson disease. Amer. J. Dance Ther. 32(1), 41 (2010). 1204 
 1205 
194. Lee MS, Lam P,  Ernst E: Effectiveness of tai chi for Parkinson’s disease: A critical review.  1206 
Parkinsonism & Related Disorders. 14, 589-594 (2008). 1207 
 1208 
195. Marjama-Lyons J et al.: Tai Chi and reduced rate of falling in Parkinson’s disease: a single 1209 
blinded pilot study. Movement Disorders. 17, S70-S71 (2002). 1210 
 1211 
196. Hackney ME, Earhart GM:  Tai Chi improves balance and mobility in people with Parkinson 1212 
disease.  Gait & Posture. 28, 456-460 (2008). 1213 
 1214 
197. Cheon SM, Sung HR, Ha MS, et al.: Tai Chi for physical and mental health of patients with 1215 
Parkinson’s disease.  In: Proceedings of the first international conference of tai chi for health. 1216 
Seoul, Republic of Korea, 68 (abstract) (2006). 1217 
 1218 
198. van der Marck MA, Kalf JG, Sturkenboom IH, Nijkrake MJ, Munneke M, Bloem 1219 
BR:Multidisciplinary care for patients with Parkinson's disease. Parkinsonism Relat. Disord. 15 1220 
Suppl 3 S219-23 (2009).  1221 
 1222 
199. Cohen DB, Oh MY, Baser SM, et al.:Fast-Track Programming and Rehabilitation Model: A 1223 
Novel Approach to Postoperative Deep Brain Stimulation Patient Care. Arch. Phys. Med. 1224 
Rehabil. 88(10), 1320-1324 (2007).  1225 
 1226 
200. Ellis T, Katz DI, White DK, DePiero TJ, Hohler AD, Saint-Hilaire M:Effectiveness of an 1227 
inpatient multidisciplinary rehabilitation program for people with Parkinson disease. Phys. Ther. 1228 
88(7), 812-819 (2008). * Presents effects of a multidisciplinary inpatient program in a large 1229 
sample of people with PD. 1230 
 1231 
201. Ellis T, de Goede CJ, Feldman RG, et al.: Efficacy of a physical therapy program in 1232 
patients with Parkinson's disease: a randomized controlled trial. Arch. Phys. Med. Rehabil. 1233 
86(4), 626-32 (2005).  1234 
 1235 
202. Trend P, Kaye J, Gage H, et al.: Short-term effectiveness of intensive multidisciplinary 1236 
rehabilitation for people with Parkinson's disease and their carers. Clin. Rehabil.16(7), 717-25 1237 
(2002).  1238 
 1239 
203. Carne W, Cifu DX, Marcinko P, et al.: Efficacy of multidisciplinary treatment program on 1240 
long-term outcomes of individuals with Parkinson's disease. J. Rehabil. Res. Dev. 42(6), 779-86 1241 
(2005). 1242 
 1243 
